# Gwo Fuang Ho

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gwo-fuang-ho/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,027 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 28 |
| i10-index | 62 |
| Last Known Institution | University Malaya Medical Centre |
| OpenAlex ID | https://openalex.org/A5012884796 |
| ORCID iD | 0000-0002-2620-9174 |
| Works | 161 |

## Researcher papers

- [Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO](https://scholariq.org/papers/pan-asian-adapted-esmo-clinical-practice-guidelines-for-the-management-of-2/)
- [Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial](https://scholariq.org/papers/pembrolizumab-versus-placebo-as-second-line-therapy-in-patients-from-asia-with/)
- [Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial)](https://scholariq.org/papers/espindolol-for-the-treatment-and-prevention-of-cachexia-in-patients-with-stage/)
- [Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline](https://scholariq.org/papers/treatment-of-patients-with-early-stage-colorectal-cancer-asco-resource/)
- [Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial](https://scholariq.org/papers/pembrolizumab-monotherapy-versus-chemotherapy-in-platinum-pretreated-recurrent/)
- [Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.](https://scholariq.org/papers/pembrolizumab-plus-best-supportive-care-versus-placebo-plus-best-supportive-care/)
- [First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial](https://scholariq.org/papers/first-line-cemiplimab-monotherapy-and-continued-cemiplimab-beyond-progression/)
- [Strain‐specific probiotic (microbial cell preparation) and omega‐3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: a randomized controlled trial](https://scholariq.org/papers/strain-specific-probiotic-microbial-cell-preparation-and-omega-3-fatty-acid-in/)
- [Effects of depression and anxiety on mortality in a mixed cancer group: a longitudinal approach using standardised diagnostic interviews](https://scholariq.org/papers/effects-of-depression-and-anxiety-on-mortality-in-a-mixed-cancer-group-a/)
- [Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline](https://scholariq.org/papers/early-detection-for-colorectal-cancer-asco-resource-stratified-guideline/)
- [P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor](https://scholariq.org/papers/p1-15-15-real-world-experience-with-afatinib-after-failure-of-first-generation/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer survivorship and care](https://scholariq.org/topics/cancer-survivorship-and-care/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

## Researcher university

- [University Malaya Medical Centre](https://scholariq.org/institutions/university-malaya-medical-centre/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.